Aim: This research sought to evaluate the anticonvulsant properties of Felodipine in a rat model of pentylenetetrazol (PTZ)-induced seizures, with a particular focus on its modulatory effects on neuroinflammatory responses and oxidative stress biomarkers.
Material and Method: The entirety of 48 male Wistar rats were separated into two main groups for behavioral and electrophysiological assessments. The anticonvulsant properties of Felodipine at dosages of 10 mg/kg and 20 mg/kg were evaluated according to seizure severity, using Racine’s Convulsion Scale and the latency to the First Myoclonic Jerk (FMJ). Electroencephalographic (EEG) recordings were analyzed to measure epileptiform activity by assessing the proportion of spike-wave discharges. Neuroinflammatory and oxidative stress markers, namely tumor necrosis factor-alpha (TNF-α) and malondialdehyde (MDA), were quantified in brain tissue using Enzyme-linked immunosorbent assay (ELISA) and Thiobarbituric Acid Reactive Substances (TBARS) tests, respectively. A p-value of less than 0.05 was deemed statistically significant.
Results: Felodipine significantly decreased seizure intensity and prolonged FMJ start time relative to the PTZ and saline-treated cohorts (p<0.05). EEG recordings revealed a marked decrease in spike percentages in the Felodipine-treated groups. Furthermore, biochemical analyses demonstrated that Felodipine significantly reduced TNF-α and MDA levels, indicating its neuroprotective effects by mitigating neuroinflammation and oxidative stress.
Conclusion: The PTZ-induced seizure model showed that felodipine significantly reduced seizure activity, neuroinflammation, and oxidative stress, indicating robust anticonvulsant and neuroprotective benefits. Its favorable safety profile and dual-action mechanism targeting calcium channels and inflammatory pathways position it as a promising candidate for epilepsy management. Further studies are warranted to explore its long-term efficacy and potential in chronic epilepsy models.
Epilepsy felodipine calcium channel blockers neuroinflammation oxidative stress anticonvulsant therapy
The experimental protocol for this study was reviewed and approved by the Animal Ethics Committee of Science University. Date: 15.01.2023, number: 0123113305.
| Birincil Dil | İngilizce |
|---|---|
| Konular | Sinirbilim (Diğer), Tıbbi Fizyoloji (Diğer) |
| Bölüm | Özgün Makaleler |
| Yazarlar | |
| Yayımlanma Tarihi | 9 Eylül 2025 |
| Gönderilme Tarihi | 4 Mart 2025 |
| Kabul Tarihi | 7 Mayıs 2025 |
| Yayımlandığı Sayı | Yıl 2025 Cilt: 7 Sayı: 3 |
Chief Editors
Prof. Dr. Berkant Özpolat, MD
Department of Thoracic Surgery, Ufuk University, Dr. Rıdvan Ege Hospital, Ankara, Türkiye
Editors
Prof. Dr. Sercan Okutucu, MD
Department of Cardiology, Ankara Lokman Hekim University, Ankara, Türkiye
Assoc. Prof. Dr. Süleyman Cebeci, MD
Department of Ear, Nose and Throat Diseases, Gazi University Faculty of Medicine, Ankara, Türkiye
Field Editors
Assoc. Prof. Dr. Doğan Öztürk, MD
Department of General Surgery, Manisa Özel Sarıkız Hospital, Manisa, Türkiye
Assoc. Prof. Dr. Birsen Doğanay, MD
Department of Cardiology, Ankara Bilkent City Hospital, Ankara, Türkiye
Assoc. Prof. Dr. Sonay Aydın, MD
Department of Radiology, Erzincan Binali Yıldırım University Faculty of Medicine, Erzincan, Türkiye
Language Editors
PhD, Dr. Evin Mise
Department of Work Psychology, Ankara University, Ayaş Vocational School, Ankara, Türkiye
Dt. Çise Nazım
Department of Periodontology, Dr. Burhan Nalbantoğlu State Hospital, Lefkoşa, North Cyprus
Statistics Editor
Dr. Nurbanu Bursa, PhD
Department of Statistics, Hacettepe University, Faculty of Science, Ankara, Türkiye
Scientific Publication Coordinator
Kübra Toğlu
argistyayincilik@gmail.com
Franchise Owner
Argist Yayıncılık
argistyayincilik@gmail.com
Publisher: Argist Yayıncılık
E-mail: argistyayincilik@gmail.com
Phone: 0312 979 0235
GSM: 0533 320 3209
Address: Kızılırmak Mahallesi Dumlupınar Bulvarı No:3 C-1 160 Çankaya/Ankara, Türkiye
Web: www.argistyayin.com.tr